- Home
- LAW vs AARD Comparison
LAW vs AARD Comparison
Compare LAW & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAW
- AARD
- Stock Information
- Founded
- LAW 2013
- AARD 2017
- Country
- LAW United States
- AARD United States
- Employees
- LAW N/A
- AARD N/A
- Industry
- LAW Computer Software: Prepackaged Software
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- LAW Technology
- AARD Health Care
- Exchange
- LAW Nasdaq
- AARD Nasdaq
- Market Cap
- LAW 249.3M
- AARD 231.9M
- IPO Year
- LAW 2021
- AARD 2025
- Fundamental
- Price
- LAW $7.09
- AARD $11.08
- Analyst Decision
- LAW Buy
- AARD Strong Buy
- Analyst Count
- LAW 2
- AARD 8
- Target Price
- LAW $7.75
- AARD $30.75
- AVG Volume (30 Days)
- LAW 156.6K
- AARD 171.0K
- Earning Date
- LAW 11-05-2025
- AARD 11-13-2025
- Dividend Yield
- LAW N/A
- AARD N/A
- EPS Growth
- LAW N/A
- AARD N/A
- EPS
- LAW N/A
- AARD N/A
- Revenue
- LAW $152,677,000.00
- AARD N/A
- Revenue This Year
- LAW $7.13
- AARD N/A
- Revenue Next Year
- LAW $6.25
- AARD N/A
- P/E Ratio
- LAW N/A
- AARD N/A
- Revenue Growth
- LAW 6.33
- AARD N/A
- 52 Week Low
- LAW $3.31
- AARD $4.88
- 52 Week High
- LAW $7.35
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- LAW 59.50
- AARD 45.65
- Support Level
- LAW $5.92
- AARD $9.34
- Resistance Level
- LAW $7.24
- AARD $10.94
- Average True Range (ATR)
- LAW 0.36
- AARD 0.82
- MACD
- LAW 0.04
- AARD -0.01
- Stochastic Oscillator
- LAW 82.03
- AARD 57.09
About LAW CS Disco Inc.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.